Lexicon Pharmaceuticals reported strong financial results with significant revenue growth and cost reductions. The progress in R&D programs and strategic partnerships further enhances the company's outlook. Despite a decrease in cash reserves, the overall sentiment of the call is positive due to the outweighing highlights.

Company Guidance -

Q3 2025

During the Lexicon Pharmaceuticals Second Quarter 2025 Financial Results Conference Call, the company provided updates on various metrics and guidance for the remainder of the year. Lexicon reported $28.9 million in revenue for Q2 2025, a significant increase from $1.6 million in Q2 2024, primarily due to $27.5 million in licensing revenue from Novo Nordisk. Research and development expenses decreased to $15.7 million, while selling, general, and administrative expenses decreased to $9.4 million. The company's net income for the quarter was $3.3 million, compared to a net loss of $53.4 million in the same period last year. Lexicon ended the quarter with $168 million in cash and investments, down from $238 million at the end of 2024. The company revised its full-year 2025 operating expense guidance, lowering it to $105-115 million from the previously announced $135-145 million, citing strategic cost reductions and the impact of the Novo licensing agreement.

Significant Revenue Increase

Lexicon reported $28.9 million in revenue for Q2 2025, compared to $1.6 million in Q2 2024, primarily driven by a $27.5 million licensing revenue from Novo Nordisk.

R&D Progress

All lead R&D programs are on track, with notable progress in pilavapadin's Phase IIb study, LX9851's IND-enabling studies, and the acceleration of sotagliflozin's Phase III SONATA study.

Strategic Partnerships

Lexicon is benefiting from strong partnerships with Novo Nordisk for LX9851 and Viatris for sotagliflozin, including new regulatory filings and approvals in various countries.

Cost Reduction and Financial Health

Operating expenses decreased by $31.9 million quarter-over-quarter, and the company lowered its operating expense projections for 2025 due to strategic repositioning.

Lexicon Pharmaceuticals (LXRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

LXRX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-0.07 / -	-0.18	―	―	―
Aug 06, 2025	2025 (Q2)	-0.07 / 0.01	-0.17	105.88% (+0.18)
May 13, 2025	2025 (Q1)	-0.10 / -0.07	-0.2	65.00% (+0.13)
Mar 06, 2025	2024 (Q4)	-0.13 / -0.09	-0.2	55.00% (+0.11)
Nov 12, 2024	2024 (Q3)	-0.16 / -0.18	-0.21	14.29% (+0.03)	―
Aug 01, 2024	2024 (Q2)	-0.18 / -0.17	-0.22	22.73% (+0.05)	―
May 02, 2024	2024 (Q1)	-0.18 / -0.20	-0.17	-17.65% (-0.03)	―
Mar 11, 2024	2023 (Q4)	-0.22 / -0.20	-0.16	-25.00% (-0.04)	―	―
Nov 08, 2023	2023 (Q3)	-0.21 / -0.21	-0.13	-61.54% (-0.08)	―
Aug 03, 2023	2023 (Q2)	-0.17 / -0.22	-0.16	-37.50% (-0.06)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

LXRX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$1.05	$1.15	+9.52%
May 13, 2025	$0.63	$0.53	-15.87%
Mar 06, 2025	$0.37	$0.39	+5.41%
Nov 12, 2024	$1.19	$1.09	-8.40%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Lexicon Pharmaceuticals (LXRX) report earnings?

Lexicon Pharmaceuticals (LXRX) is schdueled to report earning on Oct 30, 2025, Before Open (Confirmed).

What is Lexicon Pharmaceuticals (LXRX) earnings time?

Lexicon Pharmaceuticals (LXRX) earnings time is at Oct 30, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is LXRX EPS forecast?

LXRX EPS forecast for the fiscal quarter 2025 (Q3) is -0.07.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing